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Abstract It is well established that several cell surface
receptors interact with each other to form dimers and
oligomers, which are essential for their activation. Since
little is known about the quaternary structure of P2Y
receptors, in the present work, we investigated the
expression of the G-protein-coupled P2Y4 subunit as
monomeric or higher-order complex protein. We examined
both endogenously expressed P2Y4 subtype with the aid of
specific anti-P2Y4 antiserum, and heterologously trans-
fected P2Y4-tagged receptors with the use of antitag
antibodies. In both cases, we found the P2Y4 receptor
displaying molecular masses corresponding to monomeric,
dimeric and oligomeric structures. Experiments performed
in the absence of reducing agents demonstrated that there is
a strict correlation among the multiple protein bands and
that the multimeric forms are at least partially assembled by
disulphide bonds. The direct demonstration of P2Y4
homodimerisation comes instead from co–transfection and
differential co–immunoprecipitation experiments, with the
use of differently tagged P2Y4 receptors and antitag
antibodies. The structural propensity of the P2Y4 protein
to form homo-oligomers may open the possibility of a
novel regulatory mechanism of physiopathological func-




CGN Cerebellar granule neurons
DTT Dithiothreitol
FCS Foetal calf serum
GFP Green fluorescent protein
GPCRs G-protein-coupled receptors
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
SDS Sodium dodecyl sulphate
Introduction
Molecular cloning and heterologous receptor expression
studies have led to the identification and characterisation of
eight different P2Y receptor subtypes (P2Y1,2,4,6,11–14)[ 1].
P2Y1,2,4,6,11 receptors display 25–52% amino acid identity
and couple, via heterotrimeric G proteins of the Gq family, to
activation of phospholipase C, generation of inositol phos-
phates, and mobilisation of intracellular Ca
2+ stores [2, 3].
Only the P2Y11 receptor also couples to Gs proteins to
activate adenylyl cyclase and promote cyclic AMP accu-
mulation [4–6]. The recently identified P2Y12–14 receptors
have high sequence identity with each other (40–48%), but
share relatively little identity (22–25%) with the other P2Y
receptors. Moreover, differently from P2Y1,2,4,6,11 receptors,
they are associated with Gi proteins, to inhibit adenylyl
cyclase [7, 8]. P2Y receptors can alternatively be classified
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e-mail: c.volonte@inmm.cnr.itinto purinergic and pyrimidinergic subclasses. In particular,
P2Y1,11,12,13,14 receptors are activated by adenine nucleo-
tides [1]; P2Y2 and rat P2Y4 subunits display no selectivity
between ATP and UTP [9]; human P2Y4 (hP2Y4) and P2Y6
subtypes are mainly pyrimidinergic [10], but with ATP
behaving as a potent competitive antagonist at the hP2Y4
subunit [11].
One of the most broadly expressed P2Y receptor in
various brain regions is P2Y4. Highest mRNA levels are
present in the cerebellum, hypothalamus, medial frontal
gyrus, parahippocampal gyrus, striatum and thalamus;
lowest expression levels were detected in the amygdala
and spinal cord [12]. Moreover, P2Y4 mRNA was found in
the dorsal root, nodose and trigeminal ganglion [13]. In situ
hybridisation studies confirmed a similar wide distribution,
with highest incidence in the pineal gland and ventricular
system [14]. At the protein level, the presence of the P2Y4
receptor was demonstrated by immunohistochemistry in
sensory ganglia [13], the brainstem and ventral white matter
of the spinal cord during rat brain development [15].
Although according to amino acid sequence the pre-
dicted molecular mass of the P2Y4 protein is 41 kDa [14],
Western blot studies identified a protein corresponding to
88 kDa in rat cerebellar granule neurons [16, 17]. This
same high molecular weight was demonstrated in gluta-
matergic neurons from rat hippocampus, in astrocytoma
1321N1 cells stably transfected with P2Y4 receptor [18]
and in NGF-differentiated PC12 cells [19]. In rat oligoden-
drocyte precursors [20] and rat cortical astrocytes [21], the
88 kDa protein was associated with a lower molecular mass
band, of about 45 kDa, while in gerbil brain, the P2Y4
receptor displayed three bands (respectively, 75, 55 and
36 kDa) [22]. While classical studies postulated that G-
protein-coupled receptors (GPCRs) exist only as mono-
mers, many recent findings instead demonstrated that many
GPCRs form dimers and oligomers [23]. For example, it
was recently demonstrated that P2Y1 receptor forms
heterocomplexes with A1 proteins [24–26] and that P2Y4
coimmunoprecipitates with NMDA receptors [17].
Since only little is known specifically on the quaternary
structure of P2Y receptors, the purpose of the present study
was to analyse the potential expression of the P2Y4 subunit
in monomeric and higher-order complex proteins. The
attainment of this knowledge could be of great importance
in understanding the regulation and function not only of the
P2Y4 subtype but also of additional P2Y receptors.
Materials and methods
Cell line cultures
Rat phaeochromocytoma PC12nnr5 cells were cultured on
collagen-coated dishes in RPMI 1640 (Gibco BRL, MI,
Italy) medium supplemented with 10% heat-inactivated
horse serum and 5% foetal calf serum (FCS) (Gibco BRL).
Human neuroblastoma SH-SY5Y cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Sig-
ma-Aldrich, MI, Italy) supplemented with 10% FCS. All
culture media were supplemented with glutamine (2 mM),
penicillin (50 units/ml), and streptomycin (50 μg/ml), and
all cell lines were grown at 37°C in 5% CO2.
Dissociated primary cell cultures
Cerebellar granule neurons (CGN) from Wistar 8-day-old
rat cerebellum were prepared as described [27] and seeded
on poly-L-lysine-coated dishes, in Eagle’s basal medium
(BME) (Gibco BRL), with 25 mM KCl, 2 mM glutamine,
0.1 mg/ml gentamycin, and 10% heat inactivated FCS. At
1 day in vitro, cultures were supplemented with 10 μM
cytosine arabinoside and kept for 9 days, without replacing
the culture medium.
Construction of epitope-tagged human P2Y4 receptor
and transient transfection
The plasmid containing the cDNA encoding for human
P2Y4 was a kind gift from Prof. T.K. Harden. cDNA was
digested with EcoRI and XhoI restriction enzymes and
ligated into a pCMV expression vector that incorporated a
FLAG epitope tag (DYKDDDDK) at the 50 terminus.
Moreover, by the use of polymerase chain reaction (PCR)
with Platinum Pfx polymerase (Invitrogen, Paisley, UK),
human P2Y4 cDNA was amplified with oligonucleotides
containing EcoRI and XhoI restriction sequences for the
subcloning into a pCS2 plasmid containing myc epitope
tags (EQKLISEEDL) at the 50 terminus. All constructs were
verified by sequencing analysis. SH-SY5Y cells in 35-mm
plates were transiently transfected with epitope-tagged P2Y
receptor cDNAs individually or in combination. Cells were
incubated with 4 μg of total DNA and 4 μl of Lipo-
fectaminei 2000 (Invitrogen) in 2 ml of serum-free
medium (Opti-MEM, Invitrogen) for 24h.
Cell protein extraction
In order to isolate total protein extracts, cells were harvested
with ice-cold RIPA buffer [phosphate-buffered saline (PBS),
1% Nonidet P-40-NP-40-, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulphate (SDS)], whereas for immunopre-
cipitation experiments, cells were lysed in buffer G (1%
Triton X-100, 10% glycerol, 150 mM NaCl, 1,5 mM MgCl2,
1 mM CaCl2, 1 mM EGTA). Both buffers were added with
1 mM phenylmethylsulphonyl fluoride (PMSF) and 10 μg/
ml leupeptin. Cellular lysates were kept for 30 min on ice
and then centrifuged for 10 min at 14,000 × g at 4°C.
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quantification by the Bradford method [28].
Immunoprecipitation
Purified cell lysates (100 μg) were combined with 15 μl
(packed gel) of either anti-c-Myc or anti-FLAG M2 affinity
agarose (Sigma-Aldrich) and kept for 2 h at 4°C on a
rotator. The immunoadsorbents were recovered by centri-
fugation for 2 min at 3,000 × g and washed three times by
resuspension centrifugation for 2 min at 3,000 × g in buffer
G. The samples were eluted in 30 μl of sample buffer used
for SDS-polyacrylamide gel electrophoresis (PAGE).
SDS-PAGE and Western blotting analysis
Analysis of protein components was performed on 10%
polyacrylamide gels, as described (Laemmli, 1970), loading
the same amount of protein for each sample. Gels were
transferred onto nitrocellulose membranes (Amersham
Biosciences, Cologno Monzese, Italy), and blots were
probed overnight at 4°C, with anti-P2Y4 antiserum (Alo-
mone Labs, Jerusalem, Israel), (1:300), which specificity
was directly tested by immunoreactions in the presence of
the neutralising peptide (ratio 1:1 between peptide and
antiserum) or anti c-myc (9E10) antibody (Chemicon
International Inc., Temecula, CA, USA), (1:200). Subse-
quently, blots were incubated for 1 h with horseradish
peroxidase-coupled anti-rabbit (1:5,000) or anti-mouse
(1:2,500) antibodies (Cell Signaling Technology, Inc.,
Beverly, MA, USA), and visualised using electrogenerated
chemiluminescence (ECL) (Amersham Biosciences). Image
analysis and quantifications were performed by Kodak
Image Station (KDS IS440CF 1.1) with 1-dimensional (1D)
image analysis software.
Immunofluorescence analysis
SH-SY5Y cells were fixed in 4% paraformaldehyde for
15 min, washed three times with PBS, permeabilised with
0.2% Triton X-100 for 5 min, rinsed with PBS and
incubated with PBS containing 0.1% bovine serum albumin
(BSA) for 30 min. Anti-c-Myc antibody was added at a
dilution of 1:200 in PBS/BSA for 1 h. Cells were washed
and stained with Cy2-conjugated donkey anti-mouse IgG
(1:100, Jackson Immunoresearch, West Grove, PA, USA)
for 1 h, rinsed again and coverslipped with gel/mounti
anti–fading medium (Biomeda, Foster City, CA, USA).
Immunofluorescence was analysed by means of a confocal
laser scanning microscope (CLSM) (LSM 510, Carl Zeiss,
Arese, MI, Italy) equipped with an argon laser emitting at
488 nm, a helium/neon laser emitting at 543 nm and a
helium/neon laser emitting at 633 nm.
Intracellular [Ca
2+] measurements
Changes in intracellular calcium levels were investigated by
a microfluorometry imaging technique. Briefly, cells were
grown on glass coverslips to ∼80% confluence and trans-
fected with pGreen Lanterni-1 (Gibco BRL) together with
wild-type P2Y4 or tagged P2Y4 (1:8 molar ratio). After
24 h, cells were loaded with 1 mM Fura-2/AM for 30 min,
washed and placed in a recording chamber mounted on the
stage of an upright microscope (Axiscop2 FS, Carl Zeiss,
AG, Germany) equipped for infrared video microscopy
and microfluorimetry (Till Photonics GmbH, Gräfelfing,
Germany). The coverslip was continuously superfused at
2.5 ml/min with artificial cerebrospinal fluid (NaCl
126 mM, KCl 2.5 mM, NaH2PO4 1.2 mM, MgCl2
1.2 mM, CaCl2 2.4 mM, glucose 10 mM, NaHCO3
19 mM, pH 7.4, equilibrated with a mixture of O2 95% /
CO2 5%). UTP (100 μM) was delivered to the cells by bath
applications in the extracellular medium through a three-
way tap syringe for 2 min. An area of interest containing
green fluorescent protein (GFP) positive cells was chosen
and excited for 10 ms alternatively at 340 and 380 nm
wavelength for Fura-2 stimulation at 0.5 Hz. The emitted
fluorescence was acquired and digitalised by a charge-
coupled device (CCD) camera (Photonic Science, Millham,
UK). For off line analysis of the images, four regions of
interest (ROI) that included the fluorescence areas coming
from the cell body of selected GFP-positive cells were
measured. Each image was background subtracted, and a
ratio of F340/F380 was calculated.
Statistical analysis
Statistical analysis was carried out using a two-way
ANOVA, followed by a post-hoc (Newman–Keuls) test for
multiple comparisons. A value of p < 0.05 was considered
significant: *p < 0.05, **p < 0.01, ***p < 0.001.
Results
Different neuronal cell lines display two protein bands
for P2Y4 receptor
One of the earliest evidence that a receptor might form
dimers or multimers is the presence of multiple bands on
Western blot analysis. Therefore, we performed Western
blots of total protein extracted from rat phaeochromocy-
toma PC12 cell variant nnr5 and human neuroblastoma SH-
SY5Y cell line, probed with anti-P2Y4 antiserum (Figure 1).
In both cell lines, we found the presence of a low-
molecular-mass band matching the predicted monomeric
P2Y4 receptor (41 kDa) and a higher-order band with a
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bands is obtained by standard reducing [50 mM dithio-
threitol (DTT) and sample boiling] and denaturing (SDS-
PAGE) conditions. Moreover, both bands raised specific
signals, as evidenced by the lack of immunoreaction after
preadsorption of the P2Y4 antiserum with the antigen
peptide. These data support the hypothesis that both rat
and human P2Y4 receptors form stable dimers.
Tagged P2Y4 receptor is functional and displays multiple
protein bands
In order to confirm the existence of a high-molecular-mass
complex of the P2Y4 receptor, bypassing the employment
of the P2Y4 polyclonal antiserum (even though affinity
purified on immobilised antigen), we constructed tagged
P2Y4 receptors to be expressed in SH-SY5Y cells and
identified with the aid of tag-specific antibodies. Therefore,
after transient transfection of SH-SY5Y cells with Myc-
P2Y4 cDNA, we first proved by immunofluorescence that
the receptor was indeed expressed (we found expression in
25–30% of total cells, data not shown) and displayed a
distinguishable cytoplasmic and membrane localisation
(Figure 2a). We next evaluated whether the epitope-tagged
subunits retained their functional integrity by intracellular
Ca
2+ mobilisation measurements (Figure 2b–e). The addi-
tion of 100 μM UTP gave a slight Ca
2+ transient in control
SH-SY5Y cells (probably due to naive P2Y4 and P2Y6
receptors) (Figure 2b) while it determined a marked
increase in intracellular Ca
2+ in cells expressing tagged
P2Y4 receptors (Figure 2d, e), with kinetic properties
similar to their P2Y4-transfected wild-type parent
(Figure 2c, e). In addition, the immunoprecipitation of
transfected Myc-P2Y4 with anti-c-Myc antiserum (devel-
oped in rabbit) and further detection with anti-c-Myc
(9E10) antibody (developed in mouse) displayed three
signals, which were instead completely absent in the mock-
transfected sample (Figure 3). As for endogenously ex-
pressed P2Y4, we found a low-molecular-mass signal at
approximately 49 kDa, corresponding to the monomeric
Myc-P2Y4 receptor and a higher molecular band (about
100 kDa), which again resembles a potential dimeric form
of the P2Y4 subunit. This band seems peculiar for the P2Y4
receptor since transfected Myc-P2Y1, -P2Y2,- P 2 Y 6 and -
P2Y11 immunoprecipitated by the same anti-c-Myc anti-
body used for Myc-P2Y4 did not show any comparable
denaturing- and reducing-resistant signal (data not shown).
Moreover, in the upper part of the gel, we also found a
diffuse intense signal that we predict might correspond to
oligomeric forms of the P2Y4 receptor.
These findings show that the ability of endogenous P2Y4
to form high-order complexes is a property not only shown
Figure 1 Western blotting detection of P2Y4 receptor in PC12nnr5
and SH-SY5Y cells. Total protein isolated from PC12nnr5 and SH-
SY5Y were subjected to sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) on 10% polyacrylamide gel and trans-
ferred onto nitrocellulose membrane. Filters were probed with anti-
P2Y4 antiserum in the absence (−) or presence (+) of the antigen
peptide. Protein bands were detected with secondary anti-rabbit
antiserum coupled to horseradish peroxidase by electrogenerated
chemiluminescence (ECL)
Figure 2 Expression and function of tagged P2Y4 receptors. SH-
SY5Y cells transiently transfected with Myc-vector or Myc-P2Y4
were fixed, stained with anti-Myc (9E10) antibody and visualised by
Cy2-conjugated anti-mouse antibody by means of a confocal laser-
scanning microscope. Scale bar,1 0μm (a). Cells transfected for 24 h
with mock plasmid, wild-type P2Y4 or tagged P2Y4 in combination
with green fluorescent protein (GFP)-expressing plasmid were loaded
with Fura-2/AM and stimulated with 100 μM UTP for 2 min. Single
traces show the time-course of ratio values (R, F340/F380) and are
representative of intracellular Ca
2+ mobilisation of each condition
reported (b–d). The histogram (e) represents the mean amplitudes ±
standard error of mean (SEM) of the peak of background-subtracted
ratio values in respect to baseline of 18 GFP-positive wild-type
transfected cells (wt) and 28 GFP-positive tag-transfected cells (tag)
578 Purinergic Signalling (2006) 2: 575–582in different cell types in different species but also shared
with recombinant Myc-P2Y4.
Reducing conditions alter the monomeric and multimeric
ratio of P2Y4 receptor
We next analysed the effects of reducing agents on the
multiple expression of P2Y4 protein (Figure 4). In the
presence of 50 mM DTT and 5% β-mercaptoethanol (β-
ME), 80% of the total P2Y4-positive signal is given in
CGN by the 40 kDa monomeric band while the remaining
20% is constituted by the 80 kDa dimeric signal. This ratio
is then inverted when protein separation is performed in the
absence of reducing agents: the monomeric band is reduced
to 25%, and the higher molecular mass band is increased to
70% of total protein (Figure 4a). A similar situation
occurred for the transfected Myc-P2Y4 receptor. Under
reducing conditions, the oligomer represented 35% of the
total P2Y4 (instead of 55% under nonreducing conditions),
the dimer was reduced to 5% (from 20%) and the monomer
reached 65% (instead of 30%) (Figure 4b).
Myc-P2Y4 and FLAG-P2Y4 coexpresssed in SH-SY5Y
cells associate to form homo-oligomeric complexes
To provide further direct evidence that P2Y4 subunits can
form homo-oligomeric structures and to test their direct
interaction and coassembly, both the Myc- and FLAG-
tagged P2Y4 cDNAs were simultaneously cotransfected in
SH-SY5Y cells. As shown in Figure 5, only under this
condition, the immunoprecipitate of the FLAG-P2Y4
protein contained its cognate Myc-P2Y4 subunit, as
detected by Western blot using the anti-Myc (9E10)
antibody. The signal was absent after each single transfec-
tion, thus eliminating any possibility of cross-reaction of
the antibodies. Moreover, the absence of signal after in
vitro mixing of both the Myc- and FLAG-P2Y4 extracts,
also ruled out the possibility that the interaction was caused
by nonspecific receptor aggregation occurring in vitro
during cell lysis and detergent protein extraction.
Discussion
Extracellular nucleotides elicit very heterogeneous physio-
logical effects, by activating not only ionotropic P2X
Figure 4 P2Y4 protein expression under reducing and nonreducing
conditions. Total protein from cerebellar granule neurons (CGN) (a),
and Myc-precipitated proteins recovered from Myc-P2Y4- transfected
SH-SY5Y cells (b) were run on sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE) in the absence or presence of
5% β-mercaptoethanol (β-ME) and 50 mM dithiothreitol (DTT).
After immunoblotting with anti-P2Y4 or anti-c-Myc (9E10) anti-
bodies, band intensity [expressed as arbitrary units (A.U.)] was
analysed by Kodak 1.D Image Analysis software and reported as
percent of total protein expression. Data represent means ± standard
error of mean (S.E.M) from three (a) and five (b) independent
experiments. Statistical analysis was performed using a two-way
ANOVA followed by a post-hoc (Newman–Keuls) test for multiple
comparisons (*p < 0.05, **p < 0.01, ***p < 0.001)
Figure 3 Western blotting pattern of Myc-P2Y4 receptor. SH-SY5Y
cells transiently transfected with Myc-vector or Myc-P2Y4 were lysed
and immunoprecipitated with anti-c-Myc-conjugated agarose. Immu-
noadsorbents were run on 10% sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE), blotted and probed with
anti-Myc (9E10) antibody. Protein bands were detected with secondary
anti-mouse antiserum by electrogenerated chemiluminescence (ECL)
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receptors, which are both widely distributed in the central
nervous system (CNS) and peripheral nervous system
(PNS), in neuronal and glial cells. P2Y receptors are
generally present as 308–379 amino acid proteins, with a
mass ranging from 41 to 53 kDa after glycosylation. The
architecture of P2Y was studied by structural comparison
based on sequence analysis, mutagenesis and homology
modelling and established that they possess tertiary struc-
tures with seven transmembrane domains, extracellular N-
terminus and intracellular C-terminus. Very little is known,
of the possible quaternary structure of P2Y receptors. In
this context, our work greatly improves the current
knowledge about metabotropic receptors, demonstrating
that at least the P2Y4 subunit can form higher-order
complexes. These multimers appear stable, being to some
extent resistant to denaturing and reducing conditions, thus
indicating that they derive, at least in part, from covalent
disulphide bonds occurring between the subunits. More-
over, both rat and human endogenous P2Y4 receptors,
originating either from cell lines or primary neurons from
both the PNS and CNS, appear as stable dimers, and this
occurs also for the heterologous P2Y4 receptor transiently
transfected in the neuroblastoma SH-SY5Y cell line. We
would therefore consider this feature as an intrinsic
property of the P2Y4 receptor, not requiring the transfection
of auxiliary proteins in order to form oligomeric structures.
Moreover, a particularity of the P2Y4 receptor is the
absence of any potential N-glycosylation site. Since
glycosylation is a post-translational modification common
to many GPCRs involved in certain cases in the regulation
of receptor surface expression and dimerisation [29], its
potential participation in the control of P2Y4 oligomerisa-
tion can be likely ruled out.
Different authors often reported apparently conflicting
molecular masses for the P2Y4 receptor [22, 30]. It was
often postulated that the reason for this variability could
rely on post–translational modifications, diverse among
different tissues, such as glycosylation. With our work, we
now demonstrate that different aggregation states could also
account for the higher-order molecular masses reported for
the P2Y4 receptor.
Totally new within the P2Y class, our results instead
confirm what is already established for other GPCRs, which
can directly associate as either homo- or hetero-oligomers,
altering their respective pharmacology and sustaining, in this
way, different functions from that evoked by the original
receptors. For example, it is well documented that adenosine
A1 and A2A receptors form homodimers [24, 31, 32], that
these same subunits heterodimerise with dopamine D1 and
D2 receptors [33–35] or with metabotropic glutamate
receptors (mGluR) [36, 37]. Specifically within the puri-
nergic class, co–localisation at the membrane level between
the metabotropic P2Y4 and the ionotropic NMDAR1, and
their functional interplay occurring during glucose starva-
tion [17] was recently demonstrated in CGNs and human
neuroblastoma cells. Moreover, the P2Y1 subunit is able to
form heteromeric complexes with the adenosine A1
subtype [24–26], generating an adenosine receptor with
P2Y-like agonistic pharmacology. As a consequence,
adenosine 50-O-(2-thiodiphosphate), a potent P2Y1 agonist,
binds to the A1 pocket of the A1/P2Y1 complex, inhibiting
adenylyl cyclase activity via Gi/o protein and, in this way,
the hetero-oligomerisation between adenosine and P2Y
receptors might be one of the mechanisms for the adenine
nucleotide-mediated inhibition of neurotransmitter release
[38]. Since these mechanisms further generate functional
and structural heterogeneity among P2 receptors, they
certainly contribute to the explanation of how different
cells can evoke diverse responses in different tissues upon
the same kind of agonist stimulation. For example, it
appears from the literature that the ATP effect on the human
P2Y4 receptor in transfected cells is variable. ATP has been
actually described either as a partial agonist with antago-
nistic properties [39] or a full antagonist [40]. Whereas
some of the discrepancies have been ascribed to the
different receptor expression level in different transfected
cell lines, in light of our results, we can now hypothesise
that the heterogeneous behaviour exerted by ATP could
also rely on the proportion of P2Y4 oligomerisation.
Figure 5 Homo-dimerisation of tagged-P2Y4 receptor. SH-SY5Y cell
were transiently transfected with Myc-P2Y4,F L A G - P 2 Y 4 or a
combination of both tagged receptors. Solubilised proteins were
immunoprecipitated with the anti-FLAG resin and detected by
Western blot with the anti-Myc antibody. Protein bands were detected
with secondary anti-mouse antiserum by electrogenerated chemilumi-
nescence. The first lane (in vitro mix) derives from cells expressing
individual tagged receptors that were mixed during lysis and then
immunoprecipitated and detected at the above-mentioned conditions
580 Purinergic Signalling (2006) 2: 575–582Under this perspective, it is therefore noteworthy to have
established that the P2Y4 subtype can retain at least homo-
oligomeric structures, both in native and transfected cell
systems. The main physiological relevance of this investi-
gation will come from studies regarding the exact sub–
cellular localisation of the oligomeric forms of the receptor.
This and analysis of the possibility that additional P2Y
receptors might undergo homo- or hetero–multimeric
assembly are therefore our next goals.
In conclusion, since the composition of the oligomers
profoundly affects the biological response of P2 receptors
and different subtype combinations thus yield different
receptor characteristics, allowing diversity in agonists and
antagonists selectivity, transmission signalling, channel and
desensitisation properties, we do believe that the quaternary
structure of the P2Y4, among other probable P2Y receptors,
might in part contribute to explain how P2 metabotropic
subtypes can trigger so many purinergic functions.
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